Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sevoflurane
Drug ID BADD_D02015
Description Sevoflurane, also called fluoromethyl, is an ether inhalation anaesthetic agent used for the induction and maintenance of general anesthesia. It is a volatile, non-flammable, non-irritant, and easy-to-administer compound with a low solubility profile and blood-to-gas partition coefficient.
Indications and Usage Used for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.
Marketing Status Prescription
ATC Code N01AB08
DrugBank ID DB01236
KEGG ID D00547
MeSH ID D000077149
PubChem ID 5206
TTD Drug ID D0W6ZF
NDC Product Code 0074-4456; 10019-651; 0781-6160; 12164-005; 66794-015; 66794-022; 54122-4486; 10019-653; 42677-110; 66794-012; 57884-0036; 12164-009
Synonyms Sevoflurane | Fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl Ether | Fluoromethyl Hexafluoroisopropyl Ether | Sevorane | Ultane | BAX 3084
Chemical Information
Molecular Formula C4H3F7O
CAS Registry Number 28523-86-6
SMILES C(OC(C(F)(F)F)C(F)(F)F)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Cognitive disorderGlycine receptor subunit alpha-1P23415T5026925774088
Cognitive disorderApoptosis regulator BAXQ07812T8925125774088
Cognitive disorderApoptosis regulator Bcl-2P10415T3130925774088
Cognitive disorderCaspase-3P42574T5794325774088
Nerve injuryCaspase-3P42574T5794325774088
Nerve injuryApoptosis regulator BAXQ07812T8925125774088
Nerve injuryGlycine receptor subunit alpha-1P23415T5026925774088
Nerve injuryApoptosis regulator Bcl-2P49950Not Available25774088
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hiccups22.02.04.002; 07.01.06.009--
Hyperbilirubinaemia09.01.01.003; 01.06.04.003; 14.11.01.010--Not Available
Hypercapnia22.02.02.002; 14.01.04.0010.001182%Not Available
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperkalaemia14.05.03.001--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.0010.001576%
Hypertensive crisis24.08.01.0010.001182%Not Available
Hyperthermia12.05.01.002; 08.05.01.0010.000308%Not Available
Hyperthermia malignant08.05.01.0020.007881%Not Available
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hyperventilation19.01.02.004; 22.02.01.006--Not Available
Hypokalaemia14.05.03.0020.000788%
Hypophosphataemia14.04.03.001--
Hypotension24.06.03.0020.001576%
Hypothermia12.05.03.001; 08.05.01.003--
Hypoventilation22.02.01.007--Not Available
Hypoxia22.02.02.0030.001576%
Immune system disorder10.02.01.001--Not Available
Influenza like illness08.01.03.0100.000788%
Insomnia19.02.01.002; 17.15.03.002--
Intracranial pressure increased17.07.02.002--Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Lactic acidosis14.01.01.0020.001182%Not Available
Laryngospasm22.04.02.0020.001182%
Lethargy17.02.04.003; 08.01.01.008; 19.04.04.0040.000788%
Leukocytosis01.02.01.002--
Liver function test abnormal13.03.01.013--Not Available
Loss of consciousness17.02.04.004--Not Available
Metabolic acidosis14.01.01.0030.000788%Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 8 Pages